Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

News & Events

Australia’s first DNA-based COVID-19 vaccine study set to begin at The Kids Research Institute Australia

Australia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.

News & Events

The hidden burden of diabetes

When Jodie and Brad Scott welcomed their fourth child Heath into the world, they were prepared for the many sleepless nights that come with caring for newborns.

CMVictory Study

The CMVictory Study aims to learn more about the safety and effectiveness of a potential CMV vaccine.

Infectious Disease Surveillance

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au PAEDS Paediatric Active

Screen ORIGINS

Understanding how families engage with screen technologies and how it may influence child development

Pediatric Burns

This project aims to investigate the impact of a non-severe burn injury on children's health for life.

Scientific Forum Agenda

Virtual Scientific Launch Day: Wednesday 1 December 2021 (Australia) Time: 7am Australian WST/ 10am Australian EDST / 12pm NZ DST North America:

News & Events

Gifted pump proves a life changer for family

Oliver Bowman is too young to understand the enormity of having type 1 diabetes but his young parents Brooke and Aidan know all too well the reality of having a child with a chronic disease.

Research

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma

Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.

Research

Improving lung health of Aboriginal children hospitalised with chest infections – Aboriginal Children’s Excellent (ACE) Lung Health Study

The ACE project is led by Dr Pamela Laird and aims to improve post-hospitalisation follow-up of Indigenous children hospitalised with acute lower respiratory tract infections.